ResearcherDartmouth CollegeNo recent work listed

Michael Jermyn

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108691841. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2014: 2 papers

Papers 2

Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. First author DOI 10.1038/bjc.2014.95 ↗
CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. Co-author DOI 10.1088/0031-9155/59/8/1911 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tayyaba Hasan · 2 shared papers, 2014 · strength 0.08
- Paper CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. DOI 10.1088/0031-9155/59/8/1911 ↗
- Paper Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. DOI 10.1038/bjc.2014.95 ↗
Matthew Thomas Huggett · 2 shared papers, 2014 · strength 0.08
- Paper CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. DOI 10.1088/0031-9155/59/8/1911 ↗
- Paper Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. DOI 10.1038/bjc.2014.95 ↗
Brian W. Pogue · 2 shared papers, 2014 · strength 0.08
- Paper CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. DOI 10.1088/0031-9155/59/8/1911 ↗
- Paper Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. DOI 10.1038/bjc.2014.95 ↗
Stephen P. Pereira · 2 shared papers, 2014 · strength 0.08
- Paper CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. DOI 10.1088/0031-9155/59/8/1911 ↗
- Paper Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. DOI 10.1038/bjc.2014.95 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.